Clinical TrialsEnrollment into the pivotal Ph2 portion of the PYNNACLE trial evaluating rezatapopt monotherapy remains on track, with more than 75% of sites activated across the US, Europe, and Asia-Pacific.
Drug EfficacyMeaningful response rates were seen in ovarian, breast, small-cell lung, and endometrial cancer types.
Financial PerformancePMV recorded a net loss of $0.02 per share—much narrower than previously estimated net loss of $0.31 per share.